LAGUNA HILLS, Calif. / Sep 28, 2023 / Business Wire / Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the launch of its second generation CleanFlow™ Procedure Instrument. The updated procedure instrument now includes an optimized design and enhanced matrix system to improve the effectiveness and ease of use of the GentleWave Procedure. This redesigned matrix facilitates a more congruent, secure and lasting seal which provides a heightened level of consistency, further simplifying the root canal treatment process for clinicians and improving the overall patient experience. Combined with its optimized design, these changes now allow doctors to use one procedure instrument for all teeth.
“The CleanFlow Procedure Instrument with the new matrix has been unparalleled in consistency and ease of use,” said Dr. Luis Missura of Precision Endodontics. “The GentleWave Procedure gives reliable, comfortable, uncompromising disinfection that yields some of the best clinical results I’ve seen.”
Last month, Sonendo announced that its CleanFlow Procedure Instrument is now indicated for use on anterior teeth, replacing its legacy APM (Anterior Pre-Molar) Procedure Instrument. This indication, along with the new matrix system and optimized design, underscores Sonendo’s commitment to ongoing product refinement and innovation and continued investment in improving both the clinician and patient experience.
“Our top priority is our partner clinicians and their patients, so we are pleased to announce further enhancements and the launch of our second generation CleanFlow Procedure Instrument,” said Michael Smith, chief commercial officer of Sonendo. “Our goal is to help clinicians navigate the challenges of root canal therapy and provide exceptional patient care. We are confident this optimized design and enhanced matrix is the final step towards our goal of simplifying our portfolio through one procedure instrument.”
The GentleWave System is the only FDA-cleared system for root canal procedures that employs a sterilized, single-use procedure instrument to automate the cleaning and disinfection of microscopic spaces within root canals. Now, the CleanFlow Procedure Instrument is the only procedure instrument needed for the GentleWave System to treat all teeth.
The GentleWave System with CleanFlow Technology is designed for both clinicians and patients, enabling one-handed procedures and a more effective and efficient root canal treatment and offering little to no post-treatment pain and rapid healing rates. For more information on the GentleWave System, visit https://gentlewave.com/doctor/.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. Sonendo is also the parent company of TDO Software, the developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO Software integrates practice management, imaging, referral reporting and CBCT imaging, and offers built-in communication with the GentleWave System.
For more information on Sonendo, visit www.sonendo.com. For more information on the GentleWave System, visit www.gentlewave.com/doctor.
Last Trade: | US$2.47 |
Daily Volume: | 0 |
Market Cap: | US$1.030M |
November 08, 2023 October 17, 2023 August 09, 2023 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load